An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma

mRNA cancer vaccines show therapeutic potential for malignant tumors, including hepatocellular carcinoma (HCC). We optimized and synthesized stable mRNA encoding costimulator Oxford 40 ligand (OX40L). For systemic delivery, OX40L mRNAs were loaded into lipid nanoparticles (LNPs). The expression and...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2022-10, Vol.12, p.975408-975408
Main Authors: Deng, Zhuoya, Yang, Hao, Tian, Yuying, Liu, Zherui, Sun, Fang, Yang, Penghui
Format: Article
Language:English
Subjects:
hepatocellular carcinoma
immunotherapy
lipid nanoparticle
mRNA cancer vaccine
Oncology
OX40L
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:mRNA cancer vaccines show therapeutic potential for malignant tumors, including hepatocellular carcinoma (HCC). We optimized and synthesized stable mRNA encoding costimulator Oxford 40 ligand (OX40L). For systemic delivery, OX40L mRNAs were loaded into lipid nanoparticles (LNPs). The expression and costimulatory effects of OX40L were investigated in vitro . OX40L was expressed on the cell surface and costimulated T cells. In vivo , intratumoral injection of LNPs encapsulating OX40L mRNAs significantly reduced tumor growth and increased the survival of mice bearing H22 tumors. Importantly, CD4+ and CD8+ T cells were significantly increased in the OX40L mRNA group in vivo . Taken together, our findings provide a promising clinical strategy for immunotherapy for HCC using mRNA vaccines.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.975408